Myopia is generally what happens when unprecedented opportunities are placed before them. Those in the know generally do better than those in the worry. Consider Cetus, a startup biotech with a focus on a liver drug. The FDA delayed the approval of the drug, and a major funding crisis ensued. Chiron offered to take over the liabilities contingent on the sale of two patents (# 4,683,202 and # 4,683,195) to a third party, Roche Molecule for $300M (in 1993). This sale was stalled because DuPont challenged the validity of the patents, based on the formal claims written by the inventor (not a patent attorney), Kary Mullis. In the end, the soap opera turned out well for the investors with weak constitutions. For $300M, they sold the two patents to Roche, turned the company over to Chiron, and walked away. Kary Mullis won the Nobel prize for his invention embedded in these two patents, known as polymerase chain reaction (PCR) which allows DNA to be cloned. Over 4000 patents in biotech cite these original two patents. In our estimation, $300M represents "pennies on the dollar" valuation of these patents. The shareholders got a payday, and left the game. Roche on the other hand is thriving based on its intangible assets. Let IPstreet.com assist you.

The adage "you get what you pay for" certainly is meaningful in the IP legal landscape. However, it is a challenge to get new, first-time inventors in the door to start discussing why they should retain an patent lawyer. With our co-branding options, we can help advance potential clientele through your pipeline. Become a co-branding partner and we will generate a promotional code to your potential clientele that will give them a discount on our services (10% savings). When they login, your logo will be co-branded with our software, a subtle reminder to the potential client.

"The increased importance of intellectual property assets like patents and patent portfolios, along with the added complexity of valuing and analyzing risk for these information goods, has created a marketplace populated by players ill-equipped to handle the high transaction costs and information asymmetries representative of inteHectual property transactions. Accordingly, entities that can lower net transaction costs and improve information access will be able to take advantage of the unique nature of these assets." (Allen Wang, 2010, Berkeley Technology Law Journal, "Rise of the Patent Intermediaries") the tools atIPstreet.com could be a game changer.

There often comes a stage in a patent's life when a proprietor asks the question how much is my patent worth? The reasons for asking this question may vary dramatically. IP Street is the right place to help you better understand what your invention is worth and help you capitalize on your innovation by providing actionable business intelligence.